Teva Pharmaceutical Industries Other Non-Current Liabilities 2010-2024 | TEVA
Teva Pharmaceutical Industries other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Teva Pharmaceutical Industries other non-current liabilities for the quarter ending June 30, 2024 were $4.356B, a 9.64% increase year-over-year.
- Teva Pharmaceutical Industries other non-current liabilities for 2023 were $4.019B, a 1.88% increase from 2022.
- Teva Pharmaceutical Industries other non-current liabilities for 2022 were $3.945B, a 53.03% increase from 2021.
- Teva Pharmaceutical Industries other non-current liabilities for 2021 were $2.578B, a 15.09% increase from 2020.
Teva Pharmaceutical Industries Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$4,019 |
| 2022 |
$3,945 |
| 2021 |
$2,578 |
| 2020 |
$2,240 |
| 2019 |
$2,640 |
| 2018 |
$1,727 |
| 2017 |
$1,843 |
| 2016 |
$1,639 |
| 2015 |
$1,195 |
| 2014 |
$1,109 |
| 2013 |
$1,273 |
| 2012 |
$1,293 |
| 2011 |
$1,277 |
| 2010 |
$998 |
| 2009 |
$897 |
Teva Pharmaceutical Industries Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$4,356 |
| 2024-03-31 |
$3,991 |
| 2023-12-31 |
$4,019 |
| 2023-09-30 |
$3,818 |
| 2023-06-30 |
$3,973 |
| 2023-03-31 |
$3,869 |
| 2022-12-31 |
$3,945 |
| 2022-09-30 |
$3,846 |
| 2022-06-30 |
$3,842 |
| 2022-03-31 |
$3,288 |
| 2021-12-31 |
$2,578 |
| 2021-09-30 |
$2,203 |
| 2021-06-30 |
$2,215 |
| 2021-03-31 |
$2,220 |
| 2020-12-31 |
$2,240 |
| 2020-09-30 |
$2,181 |
| 2020-06-30 |
$2,411 |
| 2020-03-31 |
$2,624 |
| 2019-12-31 |
$2,640 |
| 2019-09-30 |
$2,546 |
| 2019-06-30 |
$1,642 |
| 2019-03-31 |
$1,669 |
| 2018-12-31 |
$1,727 |
| 2018-09-30 |
$1,803 |
| 2018-06-30 |
$1,814 |
| 2018-03-31 |
$1,875 |
| 2017-12-31 |
$1,843 |
| 2017-09-30 |
$1,959 |
| 2017-06-30 |
$2,038 |
| 2017-03-31 |
$1,643 |
| 2016-12-31 |
$1,639 |
| 2016-09-30 |
$1,392 |
| 2016-06-30 |
$1,353 |
| 2016-03-31 |
$1,313 |
| 2015-12-31 |
$1,195 |
| 2015-09-30 |
$1,322 |
| 2015-06-30 |
$1,341 |
| 2015-03-31 |
$1,372 |
| 2014-12-31 |
$1,109 |
| 2014-09-30 |
$1,222 |
| 2014-06-30 |
$1,000 |
| 2014-03-31 |
$960 |
| 2013-12-31 |
$1,273 |
| 2013-09-30 |
$1,817 |
| 2013-06-30 |
$1,718 |
| 2013-03-31 |
$1,322 |
| 2012-12-31 |
$1,293 |
| 2012-09-30 |
$1,281 |
| 2012-06-30 |
$1,317 |
| 2012-03-31 |
$1,276 |
| 2011-12-31 |
$1,277 |
| 2011-09-30 |
$828 |
| 2011-06-30 |
$830 |
| 2011-03-31 |
$809 |
| 2010-12-31 |
$998 |
| 2010-09-30 |
$937 |
| 2010-06-30 |
$883 |
| 2010-03-31 |
$849 |
| 2009-12-31 |
$897 |
| 2009-09-30 |
$867 |
| 2009-06-30 |
$841 |
| 2009-03-31 |
$811 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$20.120B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
